ArticleThe Journal of allergy and clinical immunology2013
Blockade of peanut allergy with a novel Ara h 2-Fcγ fusion protein in mice.
Article in The Journal of allergy and clinical immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Emerging Therapies for Anaphylaxis.Immunology and allergy clinics of North America · 2026Review
- The Etiology of IgE-Mediated Food Allergy: Potential Therapeutics and Challenges.International journal of molecular sciences · 2025Review
- Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis.The journal of allergy and clinical immunology. In practice · 2023Review
- Animal Models of IgE Anaphylaxis.Biology · 2023Review
- Oral Immunotherapy in Food Allergy: Where Are We Now?Allergy, asthma & immunology research · 2023Review
- Suppressing Immune Responses Using Siglec Ligand-Decorated Anti-receptor Antibodies.Journal of the American Chemical Society · 2022Article
- Nanoparticles Displaying Allergen and Siglec-8 Ligands Suppress IgE-FcεRI-Mediated Anaphylaxis and Desensitize Mast Cells to Subsequent Antigen Challenge.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Novel Approaches in the Inhibition of IgE-Induced Mast Cell Reactivity in Food Allergy.Frontiers in immunology · 2021Review
- Immunotherapy of Food Allergy: a Comprehensive Review.Clinical reviews in allergy & immunology · 2019Review
- CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.The Journal of clinical investigation · 2019Article
- Peptide and Recombinant Allergen Vaccines for Food Allergy.Clinical reviews in allergy & immunology · 2018Review
- Novel strategies in immunotherapy for allergic diseases.Asia Pacific allergy · 2018Review
- Allergen-specific IgG antibody signaling through FcγRIIb promotes food tolerance.The Journal of allergy and clinical immunology · 2018Article
- Adjuvanted Immunotherapy Approaches for Peanut Allergy.Frontiers in immunology · 2018Review
- Intestinal Epithelial Cells Regulate Gut Eotaxin Responses and Severity of Allergy.Frontiers in immunology · 2018Article
- The pathophysiology of anaphylaxis.The Journal of allergy and clinical immunology · 2017Review
- LPS promotes Th2 dependent sensitisation leading to anaphylaxis in a Pru p 3 mouse model.Scientific reports · 2017Article
- The future of biologics: applications for food allergy.The Journal of allergy and clinical immunology · 2015Review
- Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity.The Journal of allergy and clinical immunology · 2014Article
- Future Therapies for IgE-Mediated Food Allergy.Current pediatrics reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundConventional immunotherapy for peanut allergy using crude peanut extracts is not recommended because of the unacceptably high risk of anaphylaxis. Allergen-specific immunotherapy is not currently undertaken for peanut allergy.
objectivesThe objective of this study was to develop a novel peanut-human fusion protein to block peanut-induced anaphylaxis.
methodsWe genetically designed and expressed a novel plant-human fusion protein composed of the major peanut allergen Ara h 2 and human IgG Fcγ1. We tested the Ara h 2-Fcγ fusion protein (AHG2)'s function in purified human basophils. Transgenic mice expressing human FcεRIα and a murine peanut allergy model were used.
resultsAHG2 inhibited histamine release induced by whole peanut extract (WPE) from basophils of patients with peanut allergy, whereas the fusion protein itself did not induce mediator release. AHG2 inhibited the WPE-induced, peanut-specific, IgE-mediated passive cutaneous anaphylaxis in hFcεRIα transgenic mice. AHG2 also significantly inhibited acute anaphylactic reactivity, including the prototypical decrease in body temperature in WPE-sensitized mice challenged with crude peanut extract. Histologic evaluation of the airways showed that AHG2 decreased peanut-induced inflammation, whereas the fusion protein itself did not induce airway inflammation in peanut-sensitized mice. AHG2 did not exert an inhibitory effect in mice lacking FcγRII.
conclusionAHG2 inhibited peanut-specific IgE-mediated allergic reactions in vitro and in vivo. Linking specific peanut allergen to Fcγ can provide a new approach for the allergen immunotherapy of peanut allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.